{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:30:14Z","timestamp":1774549814059,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":765,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jbo.2012.08.001","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T01:28:38Z","timestamp":1348536518000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates\u2014Preliminary data"],"prefix":"10.1016","volume":"1","author":[{"given":"C.I.","family":"Ripamonti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maniezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Pessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cislaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2012.08.001_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1016\/j.jbo.2012.08.001_bib3","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.jbo.2012.08.001_bib4","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jebdp.2007.05.013","article-title":"Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates","volume":"7","author":"Van den Wyngaert","year":"2007","journal-title":"Journal of Evidence Based Dental Practice"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(09)72055-5","article-title":"A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"7","author":"Henry","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study","volume":"7","author":"Stopeck","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"key":"10.1016\/j.jbo.2012.08.001_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.jbo.2012.08.001_bib9","unstructured":"Food and Drug Administration, Risk evaluation and mitigation strategies (REMS) BL 125320 Prolia (denosumab). available at: \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM214883.pdf\u3009; [accesssed 23.09.10]."},{"issue":"Suppl. 5","key":"10.1016\/j.jbo.2012.08.001_bib10","first-page":"2","article-title":"American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"key":"10.1016\/j.jbo.2012.08.001_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1634\/theoncologist.2008-0209","article-title":"Bisphosphonates in oncology: rising stars or fallen heroes","volume":"14","author":"Van den Wyngaert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2012.08.001_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study","volume":"7","author":"Stopeck","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"key":"10.1016\/j.jbo.2012.08.001_bib13","doi-asserted-by":"crossref","first-page":"LCB4507","DOI":"10.1200\/jco.2010.28.18_suppl.lba4507","article-title":"randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer","volume":"28","author":"Fizazi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.jbo.2012.08.001_bib15","series-title":"Bridging the Gap Between Dental and Orthopaedic Implants","first-page":"226","article-title":"Cortical Bone Turnover and Mineral Apposition in Dental Bone Mandible","author":"Tricker","year":"2002"},{"key":"10.1016\/j.jbo.2012.08.001_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00784-009-0300-6","article-title":"Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings","volume":"14","author":"Hoefert","year":"2010","journal-title":"Clinical Oral Investigations"},{"key":"10.1016\/j.jbo.2012.08.001_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ar.a.20396","article-title":"Remodeling dynamics in the alveolar process in skeletally mature dogs","volume":"288","author":"Huja","year":"2006","journal-title":"Anatomical Record A Discoveries in Molecular, Cellular, and Evolutionary Biology"},{"issue":"10","key":"10.1016\/j.jbo.2012.08.001_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected]review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jbo.2012.08.001_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"Barasch","year":"2011","journal-title":"Journal of Dental Research"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study","volume":"47","author":"Vescovi","year":"2011","journal-title":"Oral Oncology"},{"issue":"Suppl. 8","key":"10.1016\/j.jbo.2012.08.001_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.jbo.2012.08.001_bib23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1016\/j.jbo.2012.08.001_bib24","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2012.08.001_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2012.08.001_bib26","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2012.08.001_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.jbo.2012.08.001_bib29","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.jbo.2012.08.001_bib30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of National Cancer Institute"},{"issue":"8","key":"10.1016\/j.jbo.2012.08.001_bib31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2012.08.001_bib32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"British Journal of Cancer"},{"issue":"17","key":"10.1016\/j.jbo.2012.08.001_bib33","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.jbo.2012.08.001_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1016\/j.jbo.2012.08.001_bib35","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.jbo.2012.08.001_bib36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network","volume":"20","author":"Terpos","year":"2009","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1016\/j.jbo.2012.08.001_bib37","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2012.08.001_bib39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.jbo.2012.08.001_bib40","unstructured":"Damato K, Gralow J, Hoff A, Huryn J, Ruggiero S, Schubert M, Toth B, Valero V. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. LDA Journal. 2005;64(3):21\u20134."},{"issue":"3","key":"10.1016\/j.jbo.2012.08.001_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"American Association of Oral and Maxillofacial Surgeons","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"Journal of Oncology Practice"},{"issue":"2","key":"10.1016\/j.jbo.2012.08.001_bib43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2013May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"10.1016\/j.jbo.2012.08.001_bib44","unstructured":"American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw\u20132009 update.\u3008http:\/\/www.aaoms.org\/docs\/position_papers\/bronj_update.pdf\u3009. [accessed 14.06.10]."},{"issue":"11","key":"10.1016\/j.jbo.2012.08.001_bib45","first-page":"3613","article-title":"Antibiotic prophylaxis before dental procedures can reduce onj incidence","volume":"110","author":"Montefusco","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.jbo.2012.08.001_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficay and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Preliminary results of a phase I\u2013II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral Oncology"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/0962935062000197083","article-title":"Ozone as Janus: this controversial gas can be either toxic or medically useful","volume":"13","author":"Bocci","year":"2004","journal-title":"Mediators of Inflammation"},{"issue":"2","key":"10.1016\/j.jbo.2012.08.001_bib49","first-page":"4","article-title":"[Experimental\u2013morphological study of the anti-inflammatory action of ozone-perfluorane complex application]","volume":"87","author":"Grigor'ian","year":"2008","journal-title":"Stomatologiia (Mosk)"},{"issue":"6","key":"10.1016\/j.jbo.2012.08.001_bib50","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.scs.0000249350.59096.d0","article-title":"New therapeutic protocol in the treatment of avascular necrosis of the jaws","volume":"17","author":"Agrillo","year":"2006","journal-title":"Journal of Craniofacial Surgery"},{"issue":"5","key":"10.1016\/j.jbo.2012.08.001_bib51","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/SCS.0b013e3181572609","article-title":"Ozone therapy in extractive surgery on patients treated with bisphosphonates","volume":"18","author":"Agrillo","year":"2007","journal-title":"Journal of Craniofacial Surgery"},{"issue":"5","key":"10.1016\/j.jbo.2012.08.001_bib52","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/scs.0b013e31857261f","article-title":"Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis","volume":"18","author":"Agrillo","year":"2007","journal-title":"Journal of Craniofacial Surgery"},{"issue":"9","key":"10.1016\/j.jbo.2012.08.001_bib53","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3324\/haematol.11096","article-title":"Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients","volume":"92","author":"Petrucci","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jbo.2012.08.001_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clinical Trials"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:17Z","timestamp":1761941717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137412000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S2212137412000309"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.08.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates\u2014Preliminary data","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}